GLCM Biosensor Platform
Advantages of the GLCM Biosensor Platform
GLCM is the first company to develop a repeatable and consistent electrochemical impedance spectroscopy (EIS) diagnostic biosensor – breakthrough technology
EIS method does not require modification of biomolecules with fluorescent dyes, enzymes, redox or radioactive labels
Precise results generated in under 1-minute (after assay)
Non-Invasive collection method (saliva-based)
Exceptional sensitivity and specificity that delivers the highest level of detection
Early detection of virus with very high sensitivity
Platform technology, tailorable for the detection of multiple pathogens
Cost-effective and scalable - much greater accuracy than rapid tests - more cost effective than traditional RT-PCR tests
Point of Care - Testing & Results
Point of Need
Deployable to remote areas
Capable of data capture and reporting via AI cloud-based platform
Capability to read multiple samples simultaneously, reducing the individual results time
Looking for More?
We are expanding the global economy. The GLCM Biosensor Platform technology is available to license and will be a monumental product for future generations.
Modular integrations allow our technology to communicate with microelectronics. This can be utilized for real-time updates and relaying data to human resource managers and health associations.
GLC Medical is currently seeking strategic partners and welcomes all inquiries and discussions relating to the advancement of this breakthrough detection technology.
For more information, please email us at email@example.com